Dr. Rachel Tate uptoTate
2 years 6 months ago
"In solid tumors, treat your RA patient as if they do not have a cancer, meaning do not change your therapy if the patient is responding well. Things may get dicey if hematologic malignancy." @RheumNow #RWCS24
I work w/ my onc team to ensure the patient has the needed support.
Dr. Rachel Tate uptoTate
2 years 6 months ago
Anticardiolipin ab are the most frequent aPL in SLE. Dr. M. Petri #RWCS24 @RWCSmtg @RheumNow https://t.co/cCxhctLTGf
Dr. Rachel Tate uptoTate
2 years 6 months ago
Dr. Petri reviews the 2023 ACR/APS Classification Criteria at #RWCS24 @RheumNow @RWCSmtg https://t.co/FWGsFk02Dn
Dr. Rachel Tate uptoTate
2 years 6 months ago
Steroids are associated with MACE events in RA. #RWCS24 @RheumNow @RWCSmtg https://t.co/U6ssALNspe
Dr. Rachel Tate uptoTate
2 years 6 months ago
Controversial MOSAIC results. @JointMD and @RWCSmtg discuss nuances listed below. #RWCS24 @RheumNow https://t.co/aVRJpqHuUM
Dr. Rachel Tate uptoTate
2 years 6 months ago
Who do you watch closely for developing RA? @RheumNow and @RWCSmtg suggest additional risk factors for ratcheting closer to RA. #RWCS24 https://t.co/lV3I5emn72
Dr. Rachel Tate uptoTate
2 years 6 months ago
Obese patients more likely to have a lower DMARD response compared to under/normal weighted patients. This still needs to be evaluated on a personal patient level, however, this is an important, layered discussion to have. #RWCS24 @RWCSmtg @rheumnow https://t.co/KIkVXQdcPm
Dr. John Cush RheumNow
2 years 6 months ago
Oral IL-23 Inhibitor Effective in Psoriasis
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
https://t.co/9GjR6Vx3At https://t.co/tZiykNuzKS
Dr. John Cush RheumNow
2 years 6 months ago
Mayo study of 1643 #RA pts (Dzduration 7 yrs) found 4 clusters based on # of comorbidities (Cluster 1 [42%] few comorbidities & cluster 4 [7%] > 10). Cluster 1 w/ good prog/survival; but cluster 4 was older, less DMARDs/biologics https://t.co/qAWZoXVWlv https://t.co/g3gMsNj848
Dr. John Cush RheumNow
2 years 6 months ago
Retrospective cohort analysis of 330 psoriasis pts - 83 (25%) developed #PsA after mean of 36 (3.5–114) mos. PsA Predictive factors include being female (OR=3.33), nails involved (OR=5.4), severe PSO (OR=27.4), po systemic Rx prior to PsA (4.1) https://t.co/Hpn6f1EUfD https://t.co/QanJkNi5S6
Dr. John Cush RheumNow
2 years 6 months ago
Sex Disparities in PsA/SpA
https://t.co/3pmFyo6Ztm https://t.co/zanPiI7GT5
Dr. John Cush RheumNow
2 years 6 months ago
Retrospective study of non–small cell lung cancer(NSCLC) pts Rx w/ immune checkpoint inhibitor finds that those who develop immune-related AE (irAEs) (n=803) have improved overall survival (23.7 vs 9.8 mos survival; P < .001) https://t.co/yiwJZJU10W https://t.co/fwFFlf7Q6L
RheumNow Live 2024 provided a wealth of clinical insights, particularly in the realm of rheumatoid arthritis (RA) management. Here are the top five clinical pearls from the event's opening session, "Success in Rheumatoid Arthritis."
Dr. John Cush RheumNow
2 years 6 months ago
Sarcoid arthritis (SA) seen in 19% of sarcoid pts. Metanalsysis of 49 articles (8574 pts) found Ankles most frequent (80%) followed by knees & wrists. Monoarthritis was uncommon (1%). Acute , 0-2, I2 55%). Acute SA (oligo & poly) was linked to E nodosum. https://t.co/XPbS4vVX9o https://t.co/CqonQ1a3wW
Abatacept has been studied in seropositive clinically suspect arthralgia patients (at risk for rheumatoid arthritis) and shows the potential to delay or prevent the disease.
